CN103705812B - A kind of pharmaceutical composition for the treatment of gout and its production and use - Google Patents
A kind of pharmaceutical composition for the treatment of gout and its production and use Download PDFInfo
- Publication number
- CN103705812B CN103705812B CN201410019443.5A CN201410019443A CN103705812B CN 103705812 B CN103705812 B CN 103705812B CN 201410019443 A CN201410019443 A CN 201410019443A CN 103705812 B CN103705812 B CN 103705812B
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- pharmaceutical composition
- medicine
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of pharmaceutical composition for the treatment of gout. The present invention also provides preparation method and the purposes of described pharmaceutical composition. The present invention gets after the use of the compatibility of drugs such as giant knotweed, Yanyuan violet, can eliminate patient with gout clinical symptoms as red in joint, swollen, hot, pain etc., can also reduce serum Uric Acid Concentration, gout is had to good therapeutic action, and cure rate is up to 90%, for clinical application provides new selection.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of gout and its production and use.
Background technology
Gout (gout) is that the caused a kind of crystallographic of purine metabolic disturbance and/or underexcretion is closedJoint is scorching, and clinical manifestation is hyperuricemia (hyperuricemia) and urate crystal deposition (tophus)Due to the acute and chronic arthritis of characteristic. Tophus except joint, tendon and around deposition, alsoCan be at renal deposition, and can there is urate nephropathy, uric acid lithangiuria etc., severe patient can go out kidney meritCan be incomplete. Gout is normal to occur together with obesity, hyperlipidemia, diabetes, high blood pressure and cardiovascular and cerebrovascular diseases.
Gout sees regions of the world, various nationalities. At European and American areas prevalence of hyperuricemia be2%～18%, gout is 0.13%～0.37%. The epidemiology survey demonstration of China some areas, in recent yearsThe illness rate straight line that comes China's hyperuricemia and gout rises, this may with China economic development, lifeMode changes relevant with dietary structure.
Yi nationality, distributed over Yunnan, Sichuan and Guizhou's medicine is summary of experience and the wisdom crystallization that the people of the Yi nationality, distributed over Yunnan, Sichuan and Guizhou struggle with disease for a long time, is ChinaAn important component part in the great treasure-house of medical science. Yi nationality, distributed over Yunnan, Sichuan and Guizhou's medicine number reaches thousand kinds, include animal drugs,Mineral drug, autonomic drug, be wherein no lack of the medicines such as treatment traumatic injury, chill numbness pain, if can be in Yi nationality's medicineDevelop the compound of effective treatment gout, bring new thinking will to China's gout research.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of gout. Another object of the present inventionBe to provide preparation method and the purposes of described pharmaceutical composition.
The invention provides a kind of pharmaceutical composition for the treatment of gout, it is by containing following weight proportionThe preparation that bulk drug is prepared from:
10～15 parts of giant knotweeds, 10～15 parts of bushes, 15～20 parts of Yanyuan violets, 5～10 parts, Radix Glycyrrhizae, Bi15～20 parts of Collettii, 10～15 parts of pyrrosia linguas, 10～15 parts of the rhizomes of davallia, 10～15 parts of notopterygium roots, sargentodoxa cuneata 15～20Part, 10～15 parts of Morinda officinalis, 15～20 parts of yellow angledtwig magnoliavine root stem and leafs, 5～10 parts of chrysanthemum pseudo-ginseng, 10～15 parts of smilaxs,10～15 parts of teasels, 5～10 parts, peach kernel, logical 10～15 parts of blood, 5～10 parts of cassia twig, Herba desmodii microphylli10～15 parts of 5～10 parts, tartarian buckwheat root and rhizome.
Further, it is by the bulk drug that contains following weight proportion:
15 parts of giant knotweeds, 15 parts of bushes, 20 parts of Yanyuan violets, 20 parts of 10 parts of, Bi Collettii of Radix Glycyrrhizae, pyrrosia lingua15 parts, 15 parts of the rhizomes of davallia, 15 parts of notopterygium roots, 20 parts of sargentodoxa cuneata, 15 parts of Morinda officinalis, yellow angledtwig magnoliavine root stem and leaf 20Logical 15 parts of part, 10 parts of chrysanthemum pseudo-ginseng, 15 parts of smilaxs, 15 parts of teasels, 10 parts, peach kernel, blood,10 parts of cassia twig, 10 parts of Herba desmodii microphyllis, 15 parts of tartarian buckwheat root and rhizomes.
Preferably, it is the preparation being prepared from by the bulk drug of following weight proportion:
15 parts of giant knotweeds, 15 parts of bushes, 20 parts of Yanyuan violets, 20 parts of 10 parts of, Bi Collettii of Radix Glycyrrhizae, pyrrosia lingua15 parts, 15 parts of the rhizomes of davallia, 15 parts of notopterygium roots, 20 parts of sargentodoxa cuneata, 15 parts of Morinda officinalis, yellow angledtwig magnoliavine root stem and leaf 20Logical 15 parts of part, 10 parts of chrysanthemum pseudo-ginseng, 15 parts of smilaxs, 15 parts of teasels, 10 parts, peach kernel, blood,10 parts of cassia twig, 10 parts of Herba desmodii microphyllis, 15 parts of tartarian buckwheat root and rhizomes.
The present invention's medicinal material improving eyesight used is as follows:
Wherein, described preparation is through gastrointestinal absorption preparation.
Although select in the specific embodiment of the invention through gastrointestinal absorption preparation and embody pharmaceutical compositionResult for the treatment of, but this can not be used for limiting the form of medication of pharmaceutical composition of the present invention. In conjunction with existingFor separating and purifying technology and preparation means, those skilled in the art also can be by pharmaceutical composition warp of the present inventionExtract, after purifying, be prepared into transdermal absorption formulation, external-use lotion, body and be implanted into preparation, injection etc.Other form of medication, thus strengthen target-oriented drug, improve drug effect or avoid unnecessary toxicity.
The present invention also provides the preparation method of aforementioned pharmaceutical compositions, and it comprises following operating procedure:
(1) by proportioning weighting raw materials;
(2) taking the medicinal powder of bulk drug or the water of bulk drug or extractive with organic solvent as active component, addOn pharmaceutically conventional auxiliary material be prepared into preparation.
Organic solvent of the present invention be selected from ethanol, methyl alcohol, butanols, ethyl acetate, chloroform, ether,Conventional organic solvent in the Chemistry for Chinese Traditional Medicine fields such as benzinum, the impact for fear of dissolvent residual on human body,Can preferably use ethanol.
Water extract or be used as medicine with medicinal powder, is all Chinese medicine tradition occupation mode, after water extraction, active ingredient is moltenGo out, medicine is more easily absorbed by the body, the form of medication such as onset is faster, such as decoction; Enter with former powderMedicine, the surface area of medicinal powder is larger, be also conducive to active ingredient absorption in vivo in medicinal material, but medicinal material is notThrough extracting, active ingredient still needs stripping in vivo to absorb again, and the relative water extract of its onset is slower, but also sameTime weakened the toxicity that in medicinal material, harmful components cause human body, be suitable for long-term taking, as by formerPowder is prepared into the form of medication such as pill.
The present invention also provides the purposes of aforementioned pharmaceutical compositions in the medicine of preparation treatment gout.
Further, described medicine be alleviate eliminate arthroncus, elimination or reduce tophus orReduce the medicine of serum Uric Acid Concentration.
The present invention also provides the use of aforementioned pharmaceutical compositions in the medicine of preparation treatment hyperuricemiaOn the way.
The present invention gets after the use of the compatibility of drugs such as giant knotweed, Yanyuan violet, can eliminate patient with gout clinical conditionShape is as red in joint, swollen, hot, pain etc., can also reduce serum Uric Acid Concentration, and gout is had to good treatmentEffect, and cure rate is up to 90%, for clinical application provides new selection.
Obviously, according to foregoing of the present invention, according to ordinary skill knowledge and the means of this area,Do not depart under the above-mentioned basic fundamental thought of the present invention prerequisite, can also make other various ways amendment,Replace or change.
By the form of specific embodiment, foregoing of the present invention is done further again and said in detail belowBright. But this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following embodiment. All based onThe technology that foregoing of the present invention is realized all belongs to scope of the present invention.
Detailed description of the invention
The preparation of embodiment 1 pharmaceutical composition of the present invention
Prescription:
Preparation method:
Cassia twig, notopterygium root two taste pulverizing medicinal materials become fine powder, and other medicinal material decoctings twice add 12～15 times at every turnWater gaging, merges water extraction liquid, is condensed into thick paste, mixes with cassia twig, notopterygium root medicinal powder, dry, porphyrize, mistakeSieve, mixes rear filled capsules, and sterilizing, obtains capsule, and every capsules content quality is 0.5g.
The preparation of embodiment 2 pharmaceutical compositions of the present invention
Prescription:
Giant knotweed 10g, bush 15g, Yanyuan violet 20g, Radix Glycyrrhizae 10g, Bi Collettii 20g, pyrrosia lingua 15g, boneBroken benefit 15g, notopterygium root 15g, sargentodoxa cuneata 20g, Morinda officinalis 15g, yellow angledtwig magnoliavine root stem and leaf 20g, chrysanthemum pseudo-ginseng 10g,Smilax 15g, teasel 15g, peach kernel 10g, blood logical 15g, cassia twig 10g, Herba desmodii microphylli 10g,Tartarian buckwheat root and rhizome 15g.
Preparation method:
Get each bulk drug, boiling 3 times, merges decocting liquid, obtains decoction.
The preparation of embodiment 3 pharmaceutical compositions of the present invention
Prescription:
Giant knotweed 15g, bush 10g, Yanyuan violet 15g, Radix Glycyrrhizae 5g, Bi Collettii 15g, pyrrosia lingua 10g, boneBroken benefit 10g, notopterygium root 10g, sargentodoxa cuneata 15g, Morinda officinalis 10g, yellow angledtwig magnoliavine root stem and leaf 15g, chrysanthemum pseudo-ginseng 5g, soilPoria cocos 10g, teasel 10g, peach kernel 5g, blood logical 10g, cassia twig 5g, Herba desmodii microphylli 5g, hardshipChinese bulbous onion 10g.
Preparation method:
Get each bulk drug, 70～80% alcohol refluxs extract 2 times, merge alcohol extract; Dregs of a decoction boiling 2Inferior, merge decocting liquid, alcohol extract reclaims after ethanol, merges with decocting liquid, concentrated, adds appropriate amount of starch,Granulate, obtain granule.
Illustrate beneficial effect of the present invention by test example below.
Test example 1 clinical therapeutic efficacy statistics
Gender and the range of age: contain men and women, old and young, the range of age 28-78 year, suffer from gout medical history1 month to nearly 30 years is not etc. Accept altogether 185 routine patients for medical treatment.
The present illness history of accepting patient for medical treatment is mainly: the positions such as toe joint, articulations digitorum manus, elbow joint, knee joint are anxiousProperty urarthritis outbreak once above (comprising the one-sided infringement in the first sole of the foot joint), red heat swells and ache. OftenFor discontinuity is shown effect repeatedly, there is tophus tubercle not of uniform size at the indivedual joints of ill Nian Jiuzhe or helix place,The normal supersaturation of serum Uric Acid Concentration, generally exceedes 416.2 μ mol/L. Ill severe patient, joint swelling deformation.Urine is yellow few, tanginess; Or with frequent micturition, urgent urination etc. By chemical method or polarization microscopeConfirm to contain urate crystal in tophus; By the visible IA asymmetry of X-ray examinationSwelling, or infracortical non-ulceration tumour. The resisting rheumatoid disease factor (RF) and anti-" O " are (ASO) equalIn normal reference range value.
Methods for the treatment of:
Capsule prepared by the oral embodiment of the present invention 1,, every day 3 times, 1 month is 1 by each 6The course for the treatment of, general ill 2 years with medicine for oral administration 1-2 course for the treatment of, more than 2 years, does not need 3-12 the course for the treatment of not etc.,Sick time is longer, ill more serious (tophus tubercle is multiple, and Uric Acid Content is high, arthrocele becomeShape), need the time for the treatment of longer. In 185 routine patients, some sick times are more than 2 years, and patient failsTake 3 more than the course for the treatment of by doctor's advice.
Result for the treatment of:
Have 167 example recoveries from illness, cure rate reaches 90%, by the doctor's advice clinical symptom disappearance of taking medicine, blood uric acidDrop in normal range (NR) (90-380 μ mol/L) never recurrence in 3 years;
14 routine effects are remarkable, account for 8%, clinical symptom disappearance, and blood uric acid drops to 416 μ mol/LBelow, can accidental work when not according to dietetic contraindication once;
2 routine curative effects are (wherein 1 example is taken medicine and within one week, is automatically abandoned afterwards treatment because of financial difficulties) obviously, approximatelyAccount for 1%, fail to take medicine by the course for the treatment of by doctor's advice, the clinical symptoms of red and swollen heat pain disappear substantially, slightTenderness, but passive activity is unrestricted;
2 examples not obvious (invalid), account for 1%, fail to follow the doctor's advice and take medicine by the course for the treatment of, red and swollen heat painClinical symptoms substantially disappear, moderate tenderness, passive activity is limited in 1/3, the stiff time in morning is longer.
Comprehensive the above results is known, and pharmaceutical composition cure rate of the present invention is up to 90%, and total effective rate reaches99％。
[model case]
Patient, man, 56 years old, suffers from gout existing 25 years when patient's first visit. Just start just right crus of diaphragm big footToe joint pain, afterwards two ankle-joints, both hands ten articulations digitorum manus, knee joint and elbow joint all occurred red, swollen,Heat, bitterly, in the morbidity of each position migration, discontinuity, pain when the most severe, cannot leave the bed. Existing twoThe enlargement distortion of pin big toe joint, extremities joint limitation of activity in 2/3 scope, right ankle jointThere are 3 tophus tubercles that the large grain of rice-soybean grain is not of uniform size, blood uric acid 682.0 μ mol/L. MedicationAfter one week, the pain of double-legged toe joint, two ankle-joint, ten articulations digitorum manus all obviously alleviates, and only has pressurePain, double-legged big toe swollen joint reduces, and knee joint is pain still, in extremities joint limitation of activity 1/3 scope.Take medicine after 1 month, all joints pain and double-legged big toe arthrocele phenomenon all significantly disappear, right crus of diaphragmAnkle tophus tubercle touched less than, quality of life obviously improves. Take medicine continuously after 3 months,Fully recover, blood uric acid is down to 360.5 μ mol/L. Call-on back by phone after 3 years, recurrence that so far there are no.
In sum, the present invention gets after the use of the compatibility of drugs such as giant knotweed, Yanyuan violet, can eliminate painWind patient clinical symptom is as red in joint, swollen, hot, pain etc., can also reduce serum Uric Acid Concentration, to goutHave good therapeutic action, and cure rate is up to 90%, for clinical application provides new selection.
Claims (8)
1. a pharmaceutical composition for the treatment of gout, is characterized in that: it is former by following weight proportionThe preparation that material medicine is prepared from:
10～15 parts of giant knotweeds, 10～15 parts of bushes, 15～20 parts of Yanyuan violets, 5～10 parts, Radix Glycyrrhizae, Bi15～20 parts of Collettii, 10～15 parts of pyrrosia linguas, 10～15 parts of the rhizomes of davallia, 10～15 parts of notopterygium roots, sargentodoxa cuneata 15～20Part, 10～15 parts of Morinda officinalis, 15～20 parts of yellow angledtwig magnoliavine root stem and leafs, 5～10 parts of chrysanthemum pseudo-ginseng, 10～15 parts of smilaxs,10～15 parts of teasels, 5～10 parts, peach kernel, logical 10～15 parts of blood, 5～10 parts of cassia twig, Herba desmodii microphylli10～15 parts of 5～10 parts, tartarian buckwheat root and rhizome; Sargentodoxa cuneata is selected from legume network precipice beans rattan LeguminosaeThe dry rattan of Millettiareticulata.
2. pharmaceutical composition according to claim 1, is characterized in that: it is to be joined by following weightThe preparation that the bulk drug of ratio is prepared from:
15 parts of giant knotweeds, 15 parts of bushes, 20 parts of Yanyuan violets, 20 parts of 10 parts of, Bi Collettii of Radix Glycyrrhizae, pyrrosia lingua15 parts, 15 parts of the rhizomes of davallia, 15 parts of notopterygium roots, 20 parts of sargentodoxa cuneata, 15 parts of Morinda officinalis, yellow angledtwig magnoliavine root stem and leaf 20Logical 15 parts of part, 10 parts of chrysanthemum pseudo-ginseng, 15 parts of smilaxs, 15 parts of teasels, 10 parts, peach kernel, blood,10 parts of cassia twig, 10 parts of Herba desmodii microphyllis, 15 parts of tartarian buckwheat root and rhizomes.
3. pharmaceutical composition according to claim 1 and 2, is characterized in that: described preparation is warpGastrointestinal absorption preparation.
4. the preparation method of pharmaceutical composition described in claim 1～3 any one, is characterized in that:It comprises following operating procedure:
(1) by proportioning weighting raw materials;
(2) taking the medicinal powder of bulk drug or the water of bulk drug or extractive with organic solvent as active component, addOn pharmaceutically conventional auxiliary material be prepared into preparation.
5. preparation method according to claim 4, is characterized in that: described in step (2), livePreparation method's concrete operations of property composition are as follows:
Beyond getting cassia twig, notopterygium root, other medicinal material decoctings more than 2 times, merge decocting liquid, after concentrating, with osmanthusBranch, notopterygium root medicinal powder mix, dry, obtain active component.
Described in claim 1～3 any one pharmaceutical composition in the medicine of preparation treatment goutPurposes.
7. purposes according to claim 6, is characterized in that: described medicine is to alleviate or eliminate to closeThe medicine of joint swelling, elimination or minimizing tophus or reduction serum Uric Acid Concentration.
8. described in claim 1～3 any one, pharmaceutical composition is being prepared the medicine for the treatment of hyperuricemiaPurposes in thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410019443.5A CN103705812B (en) | 2014-01-16 | 2014-01-16 | A kind of pharmaceutical composition for the treatment of gout and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410019443.5A CN103705812B (en) | 2014-01-16 | 2014-01-16 | A kind of pharmaceutical composition for the treatment of gout and its production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103705812A CN103705812A (en) | 2014-04-09 |
| CN103705812B true CN103705812B (en) | 2016-05-04 |
Family
ID=50399399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410019443.5A Active CN103705812B (en) | 2014-01-16 | 2014-01-16 | A kind of pharmaceutical composition for the treatment of gout and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103705812B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109699890A (en) * | 2019-01-11 | 2019-05-03 | 河北令生生物科技有限公司 | A kind of herbal formulation that can alleviate gout and high lithemia |
| CN116059299A (en) * | 2021-11-03 | 2023-05-05 | 朱照升 | Yi medicine composition for treating bone fracture and gout and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100421703C (en) * | 2006-06-26 | 2008-10-01 | 朱良春 | Gout granules |
| CN101264204A (en) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | Chinese medicinal composition for inhibiting uric acid and treating gout and preparation thereof |
| CN102652811A (en) * | 2012-04-12 | 2012-09-05 | 王伟 | Traditional Chinese medicine formula composition for gout treatment and preparation method thereof |
-
2014
- 2014-01-16 CN CN201410019443.5A patent/CN103705812B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103705812A (en) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102727508A (en) | Preparation of panaxadiol saponins component and pharmaceutical application for prevention and treatment of Parkinson disease | |
| CN104667044A (en) | Traditional Chinese medicine preparation for treating arthralgia and preparation method of traditional Chinese medicine preparation | |
| CN104436065A (en) | Traditional Chinese medicine for treating or preventing radiographic contrast nephropathy for imaging department and preparation method | |
| CN103705812B (en) | A kind of pharmaceutical composition for the treatment of gout and its production and use | |
| CN101347605B (en) | Chinese medicinal composition for treating gout and preparation method and application thereof | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN101978982B (en) | Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury | |
| CN105287748B (en) | The Chinese materia medica preparation and preparation method thereof for treating hyperuricemia | |
| CN101912577B (en) | Medicament for treating rheumatism and rheumatoid disease and preparation process | |
| CN100333758C (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN105434802A (en) | Pharmaceutical composition for treating diabetes, and preparation method and application thereof | |
| CN101843843A (en) | Chinese medicament for treating diabetes | |
| CN104258051A (en) | Traditional Chinese medicine composition for treating gouty arthritis, and preparation method thereof | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| CN101549075B (en) | Traditional Chinese medicine composition for treating mammary gland hyperplasia and preparation method thereof | |
| CN103610982A (en) | Medicine for treating rheumatic arthritis | |
| CN1814217B (en) | Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN104940423A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN101406556B (en) | Chinese medicine preparation for treating acute prostatitis, prostatic hyperplasia and preparation method thereof | |
| CN101524447A (en) | Pharmaceutical composition for treating constipation and preparation process thereof | |
| CN105169187B (en) | A kind of composition and its application, preparation method and drug, food containing the composition | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN102631419B (en) | Medicine composition for treating gout, as well as preparation method and application of medicine composition | |
| CN101879227B (en) | Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof | |
| CN102579601A (en) | Medicinal composition for treating rheumatoid arthritis, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |